Peripheral neuropathy in acrodermatitis chronica atrophicans - effect of treatment.
Forty-seven patients with the late borrelial manifestation acrodermatitis chronica atrophicans (ACA) and with objective neurological and/or neurophysiological findings were followed up after antibiotic treatment with dermatological, serological, neurological and neurophysiological controls. Despite a good therapeutic effect on ACA lesions, specific antibody values and symptoms of irritative nerve lesions, the objective neurological and neurophysiological findings of nerve deficit remained unchanged. There was no progress of neuropathy findings during the follow-up time. Our interpretation of the results is that the remaining neuropathy signs after treatment of ACA are neurological sequelae and not manifestations of persisting Borrelia infection.
Kindstrand
E
E
Karolinska Institute, Department of Neurology, Huddinge University Hospital, Stockholm, Sweden.
Nilsson
B Y
BY
Hovmark
A
A
Pirskanen
R
R
Asbrink
E
E
D000169:Acrodermatitis / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D025065:Borrelia burgdorferi / Q000187:drug effects / Q000472:pathogenicity*; D002444:Cefuroxime / Q000627:therapeutic use*; D004318:Doxycycline / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008193:Lyme Disease / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D011446:Prospective Studies; D013997:Time Factors
D000900:Anti-Bacterial Agents; D010406:Penicillins; D004318:Doxycycline; D002444:Cefuroxime